| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8759401 | THEA PHARMA | Aqueous gel formulation and method for inducing topical anesthesia |
Jul, 2026
(2 years from now) | |
Akten is owned by Thea Pharma.
Akten contains Lidocaine Hydrochloride.
Akten has a total of 1 drug patent out of which 0 drug patents have expired.
Akten was authorised for market use on 07 October, 2008.
Akten is available in gel;ophthalmic dosage forms.
Akten can be used as method of inducing topical anesthesia in the eye.
The generics of Akten are possible to be released after 24 July, 2026.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Oct 07, 2011 |
Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient
Market Authorisation Date: 07 October, 2008
Treatment: Method of inducing topical anesthesia in the eye
Dosage: GEL;OPHTHALMIC
More Information on Dosage
AKTEN family patents
